- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00044733
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
May 17, 2006 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
A Dose-Finding Study of the Safety of Gemtuzumab Ozogamicin as Single Agent Treatment of Patients With Relapsed Acute Myelogenous Leukemia After Autologous or Allogenic Hematopoietic Stem Cell Transplant (HSCT)
The primary objective of this study is to evaluate the safety of gemtuzumab ozogamicin in relapsed CD33-positive AML patients who received HSCT.
If the MTD dose is not reached, 9 mg/m2 will be the maximum tested dose.
A secondary objective is to assess efficacy in terms of the number of patients attaining a complete (CR) or morphological (CRp) remission.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
38
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
-
-
Connecticut
-
Hartford, Connecticut, United States, 06102
-
-
Florida
-
Jacksonville, Florida, United States, 32209
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
-
-
Kansas
-
Olathe, Kansas, United States, 66061
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
-
Trenton, New Jersey, United States, 08629
-
-
New York
-
Buffalo, New York, United States, 14215
-
Rochester, New York, United States, 14642
-
-
Ohio
-
Canton, Ohio, United States, 44708
-
-
Texas
-
Houston, Texas, United States, 77030
-
-
West Virginia
-
Charleston, West Virginia, United States, 25304
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 second and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Patients with CD33+ AML who have experienced relapse after autologous or allogeneic HSCT. Flow cytometry, performed at the study site, must demonstrate that the patient has AML that is CD33 positive, based on local laboratory criteria (Patients with history of MDS pretransplant will be eligible if their proportion of myeloblasts by marrow aspirate exceeds 5% at time of evaluation for Gemtuzumab Ozogamicin treatment)
- The patient must be greater than or equal to 60 days post-HCST
- Patients of all ages may be entered in this study
Exclusion Criteria
- Peripheral white blood count (WBC) greater than or equal to 30,000/uL at the time of initial Gemtuzumab Ozogamicin administration. (In order to reduce the peripheral blood count, patients may be treated with Hydroxyurea. Hydroxyurea must be discontinued 24 hours prior to Gemtuzumab Ozogamicin administration.)
- Known active central nervous system (CNS) or testicular leukemia at time of study entry.
- Prior therapy with anti-CD33 antibodies.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2000
Study Completion
September 1, 2004
Study Registration Dates
First Submitted
September 4, 2002
First Submitted That Met QC Criteria
September 5, 2002
First Posted (Estimate)
September 6, 2002
Study Record Updates
Last Update Posted (Estimate)
May 18, 2006
Last Update Submitted That Met QC Criteria
May 17, 2006
Last Verified
May 1, 2006
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0903X-100374
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myelogenous Leukemia
-
Masonic Cancer Center, University of MinnesotaCompletedRelapsed Acute Myelogenous Leukemia | Refractory Acute Myelogenous LeukemiaUnited States
-
Dana-Farber Cancer InstituteBoston Children's Hospital; Brigham and Women's HospitalCompletedMyelogenous Leukemia, AcuteUnited States
-
Cooperative Study Group A for HematologyCompletedACUTE MYELOGENOUS LEUKEMIAKorea, Republic of
-
Wake Forest University Health SciencesCompleted
-
Wake Forest University Health SciencesCompleted
-
Therapeutic Advances in Childhood Leukemia ConsortiumGenzyme, a Sanofi CompanyTerminatedRelapsed Acute Myelogenous LeukemiaUnited States
-
Kyowa Hakko Kirin Pharma, Inc.TerminatedAcute Myelogenous Leukemia (AML)United States
-
Hoffmann-La RocheCompletedNeoplasms, Myelogenous Leukemia, AcuteUnited States, Canada
-
Masonic Cancer Center, University of MinnesotaTerminatedAcute Myelogenous Leukemia | Refractory Acute Myelogenous LeukemiaUnited States
-
PfizerNo longer availableCD33 Positive Acute Myelogenous LeukemiaUnited States
Clinical Trials on Mylotarg (gemtuzumab ozogamicin) Injection
-
University of AarhusCompleted
-
PfizerCompletedLeukemia, Myeloid, AcuteUnited States
-
The Cleveland ClinicNational Cancer Institute (NCI); University of MichiganCompletedMyelodysplastic Syndromes | LeukemiaUnited States
-
Merck Sharp & Dohme LLCTerminatedLeukemia, Myeloid, Acute | Lymphoblastic Leukemia, Acute
-
Acute Leukemia French AssociationCompletedAcute Myeloid LeukemiaFrance
-
University Hospital HeidelbergNational Center for Tumor Diseases, HeidelbergCompletedAcute Myeloid LeukemiaGermany
-
Medical College of WisconsinCompletedRelapsed Adult AMLUnited States
-
Weill Medical College of Cornell UniversityPfizer; Jazz PharmaceuticalsTerminatedAcute Myeloid LeukemiaUnited States
-
Shaare Zedek Medical CenterRecruiting
-
University of UlmCompleted